Edwards Lifesciences Corp (EW) - Total Assets
Based on the latest financial reports, Edwards Lifesciences Corp (EW) holds total assets worth $13.32 Billion USD as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Explore EW operating cash to total liabilities to assess how comfortably operating cash covers total debt obligations.
Edwards Lifesciences Corp - Total Assets Trend (1999–2025)
This chart illustrates how Edwards Lifesciences Corp's total assets have evolved over time, based on quarterly financial data. See net assets of Edwards Lifesciences Corp for net asset value and shareholders' equity analysis.
Edwards Lifesciences Corp - Asset Composition Analysis
Current Asset Composition (December 2025)
Edwards Lifesciences Corp's total assets of $13.32 Billion consist of 49.2% current assets and 50.8% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $2.94 Billion | 21.5% |
| Accounts Receivable | $912.10 Million | 6.7% |
| Inventory | $1.13 Billion | 8.2% |
| Property, Plant & Equipment | $1.91 Billion | 14.0% |
| Intangible Assets | $1.13 Billion | 8.2% |
| Goodwill | $1.77 Billion | 12.9% |
Asset Composition Trend (1999–2025)
This chart illustrates how Edwards Lifesciences Corp's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see EW market cap overview.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Edwards Lifesciences Corp's current assets represent 49.2% of total assets in 2025, an increase from 24.8% in 1999.
- Cash Position: Cash and equivalents constituted 21.5% of total assets in 2025, up from 0.0% in 1999.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 20.0% of total assets, a decrease from 68.0% in 1999.
- Asset Diversification: The largest asset category is cash and equivalents at 21.5% of total assets.
Edwards Lifesciences Corp Competitors by Total Assets
Key competitors of Edwards Lifesciences Corp based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
DexCom Inc
NASDAQ:DXCM
|
USA | $6.63 Billion |
|
Medprin Regenerative Medical Technologies Co. Ltd.
SHE:301033
|
China | CN¥805.10 Million |
|
Shanghai Aohua Photoelectricity Endoscope Co. Ltd. A
SHG:688212
|
China | CN¥1.86 Billion |
|
Shanghai ZJ Bio-Tech Co. Ltd. A
SHG:688317
|
China | CN¥3.71 Billion |
|
Theradiag SA
PA:ALTHE
|
France | €11.55 Million |
|
Corentec Co Ltd
KQ:104540
|
Korea | ₩175.16 Billion |
|
Adherium Ltd
AU:ADR
|
Australia | AU$4.16 Million |
|
Atomo Diagnostics Ltd
AU:AT1
|
Australia | AU$9.48 Million |
Edwards Lifesciences Corp - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 4.42 | 4.45 | 3.75 |
| Quick Ratio | 3.63 | 3.66 | 2.89 |
| Cash Ratio | 0.00 | 2.25 | 1.48 |
| Working Capital | $4.82 Billion | $4.82 Billion | $2.44 Billion |
Edwards Lifesciences Corp - Advanced Valuation Insights
This section examines the relationship between Edwards Lifesciences Corp's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 4.79 |
| Latest Market Cap to Assets Ratio | 3.62 |
| Asset Growth Rate (YoY) | 4.9% |
| Total Assets | $13.70 Billion |
| Market Capitalization | $49.56 Billion USD |
Valuation Analysis
Premium Asset Valuation: The market values Edwards Lifesciences Corp's assets at a significant premium (3.62x), suggesting investors see substantial growth potential or unique competitive advantages.
Positive Asset Growth: Edwards Lifesciences Corp's assets grew by 4.9% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for Edwards Lifesciences Corp (1999–2025)
The table below shows the annual total assets of Edwards Lifesciences Corp from 1999 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $13.70 Billion | +4.92% |
| 2024-12-31 | $13.06 Billion | +39.43% |
| 2023-12-31 | $9.36 Billion | +12.91% |
| 2022-12-31 | $8.29 Billion | -2.47% |
| 2021-12-31 | $8.50 Billion | +17.49% |
| 2020-12-31 | $7.24 Billion | +11.54% |
| 2019-12-31 | $6.49 Billion | +21.87% |
| 2018-12-31 | $5.32 Billion | -6.54% |
| 2017-12-31 | $5.70 Billion | +26.31% |
| 2016-12-31 | $4.51 Billion | +11.10% |
| 2015-12-31 | $4.06 Billion | +15.18% |
| 2014-12-31 | $3.52 Billion | +29.35% |
| 2013-12-31 | $2.72 Billion | +22.65% |
| 2012-12-31 | $2.22 Billion | +12.17% |
| 2011-12-31 | $1.98 Billion | +12.07% |
| 2010-12-31 | $1.77 Billion | +9.39% |
| 2009-12-31 | $1.62 Billion | +15.38% |
| 2008-12-31 | $1.40 Billion | +4.10% |
| 2007-12-31 | $1.35 Billion | +7.88% |
| 2006-12-31 | $1.25 Billion | +1.44% |
| 2005-12-31 | $1.23 Billion | +10.46% |
| 2004-12-31 | $1.11 Billion | +1.03% |
| 2003-12-31 | $1.10 Billion | +9.24% |
| 2002-12-31 | $1.01 Billion | +3.62% |
| 2001-12-31 | $973.00 Million | -10.57% |
| 2000-12-31 | $1.09 Billion | -24.29% |
| 1999-12-31 | $1.44 Billion | -- |
About Edwards Lifesciences Corp
Edwards Lifesciences Corporation provides products and technologies to treat advanced cardiovascular diseases in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to t… Read more